Longevity Health Weighs Alternatives for Bioaesthetic and Therapeutics Businesses to Maximize Value
Key Facts
Longevity Health Holdings’ board of directors announced on November 11, 2026, that it is exploring and evaluating strategic alternatives for the company’s bioaesthetics and therapeutics businesses, with the aim of maximizing value for the company and its stakeholders, according to a summary of the news reported in a GlobeNewswire brief. The company said in the text quoted from the announcement that the board “is exploring and evaluating strategic alternatives” for these businesses. The announcement puts a review of the two business units at the forefront of developments, but does not in itself mean a deal has been reached. Details of the options the board is considering or a timetable for the process could not be confirmed from an open source. The company’s shares trade under the ticker XAGE on the OTCQB market.
The review follows the settlement of a legal dispute with Puritan Partners. The company disclosed to the U.S. Securities and Exchange Commission that it entered into a settlement agreement on August 13, 2026, with its subsidiary Carmell Regen Med Corporation, to resolve the lawsuit between the parties. The company said in a settlement statement that the dispute, which had been ongoing since November 2023, had hampered its ability to raise capital and pursue strategic opportunities. The disclosure provides a timeline for the board’s decision, but does not establish a direct link between the settlement and the start of the review. It also does not show that the settlement led to new financing or an agreement on any of the alternatives.
In the context of its financing relationship with Puritan, Longevity disclosed a securities purchase agreement entered into on August 31, 2026, after the settlement agreement. Under the agreement, the company issued a 10% interest-bearing secured convertible note, due on February 29, 2028, according to its SEC disclosure. The disclosure describes Puritan as an existing investor in the company. These terms outline a financial aspect of the relationship between the parties during 2026, alongside the earlier legal settlement. The disclosure does not indicate whether the note or its terms are part of the current strategic review.
The latest financial data in the quarterly report show net sales fell to $395,991 in the second quarter of 2026, from $503,612 in the same quarter of 2025. For the first half, sales totaled $787,755, compared with $1,013,965 in the same period a year earlier. These figures provide a picture of the company’s performance before the review was announced in November and do not represent results for a later period. The report also showed cash and cash equivalents of $35,471 on June 30, 2026, compared with $706,740 on December 31, 2025. These figures cover two different periods: a cash balance at the end of June and a year-end balance for the prior year.
The report described the company as operating in bioaesthetics and selling skin and hair care products, while noting that research and development of its regenerative bone and tissue products had been halted. The company said its cosmetic products are sold mainly in the United States through three channels: business-to-business, direct-to-consumer and distributors. This description places the existing cosmetics business alongside the therapeutics businesses covered by the board’s announcement. The report also defines the scope of the company’s commercial activity as stated in its disclosure for the period ended June 30, 2026. The announcement published in a GlobeNewswire brief provided no further details on the valuation of each business or plans to resume the halted research.
The available share price data before the announcement show a close at $0.103 on November 9, 2026, the same price recorded on November 6. The close was $0.11 on November 4. These are dated figures that precede the November 11 announcement, so they do not describe the market’s response to the news. The available evidence does not include a subsequent close or a daily move linked to the announcement. The next development to watch is whether the board announces details of the review process or a tangible outcome, as no timetable or specific options for the process could be confirmed from an open source.